Bruno Rocha de Avila Pelozin

Prof. Bruno Rocha de Avila Pelozin

Master Student in Science
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
CCCamila Caldas Correia
Camila Caldas Correia
LRLuis Felipe Rodrigues
Luis Felipe Rodrigues
Bruno Rocha de Avila PelozinBruno Rocha de Avila Pelozin
Bruno Rocha de Avila Pelozin
Edilamar Menezes OliveiraEdilamar Menezes Oliveira
Edilamar Menezes Oliveira
Tiago FernandesTiago Fernandes
Tiago Fernandes
Despite advances in treatments and therapies, cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide. The discovery that most of the human genome, although transcribed, does not encode proteins was crucial for focusing on the potential of long non-coding RNAs (lncRNAs) as essential regulators of cell function at the epigenetic, transcriptional, and post-transcriptional levels. This class of non-coding RNAs is related to the pathophysiology of the cardiovascular system. The different expression profiles of lncRNAs, in different contexts of CVDs, change a great potential in their use as a biomarker and targets of therapeutic intervention. Furthermore, regular physical exercise plays a protective role against CVDs; on the other hand, little is known about its underlying molecular mechanisms. In this review, we look at the accumulated knowledge on lncRNAs and their functions in the cardiovascular system, focusing on the cardiovascular pathology of arterial hypertension, coronary heart disease, acute myocardial infarction, and heart failure. We discuss the potential of these molecules as biomarkers for clinical use, their limitations, and how the manipulation of the expression profile of these transcripts through physical exercise can begin to be suggested as a strategy for the treatment of CVDs.

1 January 2022 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
Bruno Rocha de Avila PelozinBruno Rocha de Avila Pelozin
Bruno Rocha de Avila Pelozin
USUrsula P. R. Soci
Ursula P. R. Soci
JGJoão L. P. Gomes
João L. P. Gomes
EOEdilamar M. Oliveira
Edilamar M. Oliveira
Tiago FernandesTiago Fernandes
Tiago Fernandes
Aerobic exercise training (ET) promotes cardiovascular adaptations, including physiological left ventricular hypertrophy (LVH). However, the molecular mechanisms underlying these changes are unclear. The study aimed to elucidate specific microRNAs (miRNAs) and target genes involved with the protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in high-volume ET-induced LVH. Eight-week-old female Wistar rats were assigned to three groups: sedentary control (SC), trained protocol 1 (P1), and trained protocol 2 (P2). P1 consisted of 60 min/day of swimming, 5 times/wk, for 10 wk. P2 consisted of the same protocol as P1 until the 8th week; in the 9th week rats trained 2 times/day, and in the 10th week they trained 3 times/day. Subsequently, structure and molecular parameters were evaluated in the heart. Trained groups demonstrate higher values of peak oxygen uptake (V˙O2peak ), exercise tolerance, and LVH in a volume-dependent manner. The miRNA-26a-5p levels were higher in P1 and P2 compared with the SC group (150 ± 15%, d = 1.8; 148 ± 16%, d = 1.7; and 100 ± 7%, respectively; P < 0.05). In contrast, miRNA-16-5p levels were lower in P1 and P2 compared with the SC group (69 ± 5%, d = 2.3, P < 0.01; 37 ± 4%, d = 5.6, P < 0.001; and 100 ± 6%, respectively). Additionally, miRNA-16-5p knockdown and miRNA-26a-5p overexpression significantly promoted cardiomyocyte hypertrophy in neonatal rat cardiomyocytes. Both miRNAs were selected, with the DIANA Tools bioinformatics website, for acting in the mTOR signaling pathway. The protein expression of AKT, MTOR, ribosomal protein S6 kinase beta-1 (P70S6K), and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) were greater in P1 and even more pronounced in P2. Nonetheless, glycogen synthase kinase 3 beta (GSK3β) protein expression was lower in trained groups. Together, these molecular changes may contribute to a pronounced physiological LVH observed in high-volume aerobic training. NEW & NOTEWORTHY Physiological hypertrophic growth of the heart as a compensatory response to exercise training (ET) is coupled with recent progress in dissecting the microRNA (miRNA)-mediated molecular basis of hypertrophy. Aerobic ET seems to reduce miRNA-16-5p and increase miRNA-26a-5p expression in a volume-dependent mode, activating protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathways, and likely produces an enhanced left ventricular hypertrophy (LVH) in high-volume endurance training. New insight into these mechanisms can be useful in understanding physiological LVH and how it might be harnessed as a therapeutic application.

29 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
NJNatan da Silva Junior
Natan da Silva Junior
AAAluisio Andrade-Lima
Aluisio Andrade-Lima
MCMarcel R. Chehuen
Marcel R. Chehuen
Anthony LeichtAnthony Leicht
Anthony Leicht
PBPatricia Brum
Patricia Brum
CFClaudia L. M. Forjaz
Claudia L. M. Forjaz
Patients with peripheral artery disease (PAD) have reduced muscle capillary density. Walking training (WT) is recommended for PAD patients. The goal of the study was to verify whether WT promotes angiogenesis in PAD-affected muscle and to investigate the possible role of miRNA-126 and the vascular endothelium growth factor (VEGF) angiogenic pathways on this adaptation. Thirty-two men with PAD were randomly allocated to two groups: WT (n = 16, 2 sessions/week) and control (CO, n = 16). Maximal treadmill tests and gastrocnemius biopsies were performed at baseline and after 12 weeks. Histological and molecular analyses were performed by blinded researchers. Maximal walking capacity increased by 65% with WT. WT increased the gastrocnemius capillary-fiber ratio (WT = 109 ± 13 vs. 164 ± 21 and CO = 100 ± 8 vs. 106 ± 6%, p < 0.001). Muscular expression of miRNA-126 and VEGF increased with WT (WT = 101 ± 13 vs. 130 ± 5 and CO = 100 ± 14 vs. 77 ± 20%, p < 0.001; WT = 103 ± 28 vs. 153 ± 59 and CO = 100 ± 36 vs. 84 ± 41%, p = 0.001, respectively), while expression of PI3KR2 decreased (WT = 97 ± 23 vs. 75 ± 21 and CO = 100 ± 29 vs. 105 ± 39%, p = 0.021). WT promoted angiogenesis in the muscle affected by PAD, and miRNA-126 may have a role in this adaptation by inhibiting PI3KR2, enabling the progression of the VEGF signaling pathway.

28 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
LRLuis Felipe Rodrigues
Luis Felipe Rodrigues
Bruno Rocha de Avila PelozinBruno Rocha de Avila Pelozin
Bruno Rocha de Avila Pelozin
NJNatan da Silva Junior
Natan da Silva Junior
USUrsula Paula Renó Soci
Ursula Paula Renó Soci
ECEverton Crivoi Do Carmo
Everton Crivoi Do Carmo
Tiago FernandesTiago Fernandes
Tiago Fernandes
Aerobic exercise training (ET) produces beneficial adaptations in skeletal muscles, including angiogenesis. The renin–angiotensin system (RAS) is highly involved in angiogenesis stimuli. However, the molecular mechanisms underlying capillary growth in skeletal muscle induced by aerobic ET are not completely understood. This study aimed to investigate the effects of volume-dependent aerobic ET on skeletal muscle angiogenesis involving the expression of miRNAs-27a and 27b on RAS and oxidant–antioxidant balance. Eight-week-old female Wistar rats were divided into three groups: sedentary control (SC), trained protocol 1 (P1), and trained protocol 2 (P2). P1 consisted of 60 min/day of swimming, 5×/week, for 10 weeks. P2 consisted of the same protocol as P1 until the 8th week, but in the 9th week, rats trained 2×/day, and in the 10th week, trained 3×/day. Angiogenesis and molecular analyses were performed in soleus muscle samples. Furthermore, to establish ET-induced angiogenesis through RAS, animals were treated with an AT1 receptor blocker (losartan). Aerobic ET promoted higher VO2 peak and exercise tolerance values. In contrast, miRNA-27a and -27b levels were reduced in both trained groups, compared with the SC group. This was in parallel with an increase in the ACE1/Ang II/VEGF axis, which led to a higher capillary-to-fiber ratio. Moreover, aerobic ET induced an antioxidant profile increasing skeletal muscle SOD2 and catalase gene expression, which was accompanied by high nitrite levels and reduced nitrotyrosine concentrations in the circulation. Additionally, losartan treatment partially re-established the miRNAs expression and the capillary-to-fiber ratio in the trained groups. In summary, aerobic ET promoted angiogenesis through the miRNA-27a/b–ACE1/Ang II/VEGF axis and improved the redox balance. Losartan treatment demonstrates the participation of RAS in ET-induced vascular growth. miRNAs and RAS components are promising potential targets to modulate angiogenesis for combating vascular diseases, as well as potential biomarkers to monitor training interventions and physical performance.

17 October 2025 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
VJVictor Hugo Antonio Joaquim
Victor Hugo Antonio Joaquim
NPNoemy Pinto Pereira
Noemy Pinto Pereira
Alex Cleber Improta CariaAlex Cleber Improta Caria
Alex Cleber Improta Caria
Bruno Rocha de Avila PelozinBruno Rocha de Avila Pelozin
Bruno Rocha de Avila Pelozin
Tiago FernandesTiago Fernandes
Tiago Fernandes
Edilamar Menezes OliveiraEdilamar Menezes Oliveira
Edilamar Menezes Oliveira

1 January 2025 in Clinical Hypertension
Verified
Journal Article
Open access
PDF file
LSLeôncio Lopes Soares
Leôncio Lopes Soares
Luciano Bernardes LeiteLuciano Bernardes Leite
Luciano Bernardes Leite
Bruno Rocha de Avila PelozinBruno Rocha de Avila Pelozin
Bruno Rocha de Avila Pelozin
SCSebastião FELIPE FERREIRA Felipe Ferreira Costa
Sebastião FELIPE FERREIRA Felipe Ferreira Costa
TIThainá Iasbik-Lima
Thainá Iasbik-Lima
ANANTONIO JOSE NATALI
ANTONIO JOSE NATALI
Soares LL, et al. Clin Hypertens. 2025 Dec;31:e39. https://doi.org/10.5646/ch.2025.31.e39